arginine and per977

arginine has been researched along with per977 in 44 studies

Research

Studies (44)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	37 (84.09)	24.3611
2020's	7 (15.91)	2.80

Authors

Authors	Studies
Ansell, JE; Bakhru, SH; Brown, K; Costin, JC; Dishy, V; Grosso, M; Laulicht, BE; Noveck, RJ; Steiner, SS	1
Ansell, J; Bakhru, S; Costin, J; Laulicht, B; Steiner, S	1
Berkowitz, SD; Costin', J; Curnutte, JT; Gibson, CM; Hoffman, M; Kaminskas, E; Kowey, PR; Krucoff, MW; Levy, JH; Mintz, PD; Reilly, PA; Sager, PT; Sarich, TC; Seltzer, JH; Singer, DE; Stockbridge, N; Weitz, JI	1
Crowther, M; Crowther, MA	1
Cuker, A; Siegal, D	1
Agewall, S; Atar, D; Drexel, H; Husted, SE; Kaski, JC; Kjeldsen, K; Koller, L; Lewis, BS; Lip, GYH; Morais, J; Niessner, A; Storey, RF; Tamargo, J; Torp-Pedersen, C; Verheugt, FWA; Wassmann, S	1
Gómez-Outes, A; Lecumberri, R	1
Ansell, JE	1
Ageno, W; Chan, NC; Crowther, M; Levy, JH; Verhamme, P; Weitz, JI	1
Asirvatham, SJ; Hu, TY; Vaidya, VR	1
Askar, W; Atwal, D; Augoustides, JG; Ghadimi, K; Gutsche, JT; Lohrmann, GM; Makar, G; Patel, PA; Ramakrishna, H; Shamoun, FE	1
Ghosh, J; Hague, A; Pinho-Gomes, AC	1
Fanikos, J; Smythe, MA; Trujillo, T	1
Hussain, SS; Mukherjee, D; Tyroch, AH	1
Kaminskas, E; Reiffel, JA; Reilly, P; Sager, P; Sarich, T; Seltzer, J; Weitz, JI	1
Antman, EM; Giugliano, RP; Ruff, CT	1
Ansell, JE; Bakhru, SH; Costin, JC; Hoffman, M; Laulicht, BE; Steiner, SS	1
Arbit, B; Hsu, JC; Nishimura, M	1
Eikelboom, JW; Weitz, JI	1
Fanikos, J; Huisman, MV	2
Levy, JH	2
Kaatz, S; Milling, TJ	2
Pollack, CV	1
Ansell, JE; Bakhru, SH; Brown, K; Costin, JC; Dishy, V; Grosso, MA; Lanz, HJ; Laulicht, BE; Mercuri, MF; Noveck, RJ; Steiner, SS	1
Bhagirath, VC; Eikelboom, JW; Monagle, S; Ng, KH	1
Desborough, MJ; Shapiro, S; Zhang, XY	1
Gkiatas, I; Korompilias, AV; Kostas-Agnantis, I; Papadopoulos, DV; Tsantes, AG; Ziara, P	1
Fischer, AM; Godier, A; Martin, AC; Mauge, L; Smadja, DM	1
Almegren, M	1
Douketis, J; Levy, JH; Weitz, JI	1
Amin-Hanjani, S; Becker, KJ; Bennett, DA; Bernhardt, J; Dichgans, M; Ford, GA; Goldstein, LB; Goyal, M; Greenberg, SM; Howard, G; Keller, E; Kidwell, CS; Olivot, JM; Pantoni, L; Pierot, L; Planas, AM; Reeves, M; Saposnik, G; Strbian, D; Thrift, A; Tymianski, M; Woo, D; Yenari, MA; Zorowitz, RD	1
Abbina, S; Conley, PB; Creagh, AL; Haynes, C; Kalathottukaren, MT; Karbarz, MJ; Kizhakkedathu, JN; Lu, G; Pandey, A	1
Ageno, W; Agnelli, G; Chan, NC; De Caterina, R; Diener, HC; Hylek, E; Lip, GYH; Raskob, GE; Siegal, DM; Verheugt, FWA; Weitz, JI	1
Bhatt, SH; Dobesh, PP; Glaubius, K; Trujillo, TC	1
Gulseth, MP; Kaide, CG	1
Bari, N; Ho, JPK; Riffat, F	1
Ansell, J; Baker, C; Bakhru, SH; Burnett, A; Chen, L; Jiang, X; Laulicht, BE; Steiner, S; Villano, S	1
Siegal, DM	1
Ansell, J; Bakhru, S; Freedman, D; Laulicht, BE; Tracey, G; Villano, S	1
Chan, NC; Weitz, JI	1
Jung, C; Leentjens, J; Middeldorp, S	1

Reviews

31 review(s) available for arginine and per977

Article	Year
Reversal agents in development for the new oral anticoagulants. Postgraduate medicine, 2014, Volume: 126, Issue:7 Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Arginine; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa; Factor Xa Inhibitors; Humans; Piperazines; Recombinant Proteins; Thromboembolism	2014
Antidotes for novel oral anticoagulants: current status and future potential. Arteriosclerosis, thrombosis, and vascular biology, 2015, Volume: 35, Issue:8 Topics: Administration, Oral; Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Arginine; Blood Coagulation; Coagulants; Hemorrhage; Humans; Piperazines; Risk Assessment; Risk Factors; Treatment Outcome	2015
Monitoring and reversal of direct oral anticoagulants. Hematology. American Society of Hematology. Education Program, 2015, Volume: 2015 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Blood Coagulation Factors; Blood Coagulation Tests; Dabigatran; Factor VIIa; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hemostasis; Humans; Partial Thromboplastin Time; Piperazines; Prothrombin; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Thrombin Time	2015
Reversing the Effect of Oral Anticoagulant Drugs: Established and Newer Options. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2016, Volume: 16, Issue:3 Topics: Administration, Oral; Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Arginine; Blood Coagulation Disorders; Blood Coagulation Factors; Coagulants; Combined Modality Therapy; Dabigatran; Drugs, Investigational; Enoxaparin; Factor Xa; Fibrinolytic Agents; Humans; Piperazines; Practice Guidelines as Topic; Recombinant Proteins; Vitamin K	2016
When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. Journal of thrombosis and haemostasis : JTH, 2016, Volume: 14, Issue:3 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Arginine; Blood Coagulation; Coagulants; Factor Xa; Hemorrhage; Humans; Piperazines; Recombinant Proteins	2016
Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vascular health and risk management, 2016, Volume: 12 Topics: Administration, Oral; Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Arginine; Blood Coagulation; Blood Coagulation Tests; Coagulants; Drug Monitoring; Factor Xa; Hemorrhage; Humans; Piperazines; Recombinant Proteins	2016
Reversal Agents for the New Generation of Oral Anticoagulants: Implications for the Perioperative Physician. Journal of cardiothoracic and vascular anesthesia, 2016, Volume: 30, Issue:3 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Blood Coagulation Factors; Factor VIIa; Factor Xa; Factor Xa Inhibitors; Humans; Piperazines; Recombinant Proteins; Renal Dialysis	2016
Management of novel oral anticoagulants in emergency and trauma surgery. The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland, 2016, Volume: 14, Issue:4 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Arginine; Blood Coagulation Factors; Emergency Treatment; Female; Humans; Male; Piperazines; Postoperative Hemorrhage; Preoperative Care; Primary Prevention; Prognosis; Risk Assessment; Treatment Outcome; Wounds and Injuries	2016
Reversal agents for use with direct and indirect anticoagulants. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2016, May-15, Volume: 73, Issue:10 Suppl 2 Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Piperazines; Recombinant Proteins	2016
Reversal of Newer Direct Oral Anticoagulant Drugs (DOACs). Cardiovascular & hematological agents in medicinal chemistry, 2017, Volume: 14, Issue:2 Topics: Administration, Oral; Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Antifibrinolytic Agents; Arginine; Blood Coagulation; Blood Coagulation Factors; Cardiovascular Diseases; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Models, Molecular; Piperazines; Recombinant Proteins	2017
NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank. American heart journal, 2016, Volume: 177 Topics: Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Arginine; Atrial Fibrillation; Congresses as Topic; Dabigatran; Drug Monitoring; Factor Xa; Factor Xa Inhibitors; Humans; Partial Thromboplastin Time; Piperazines; Product Surveillance, Postmarketing; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thiazoles; Thrombin Time; Venous Thromboembolism	2016
Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents. Circulation, 2016, Jul-19, Volume: 134, Issue:3 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Antithrombins; Arginine; Blood Coagulation Factors; Dabigatran; Factor VIIa; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Piperazines; Plasma; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles	2016
Reversal agents for direct oral anticoagulants: A focused review. International journal of cardiology, 2016, Nov-15, Volume: 223 Topics: Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Factor Xa; Humans; Piperazines; Recombinant Proteins	2016
Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols. The American journal of medicine, 2016, Volume: 129, Issue:11S Topics: Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Arginine; Blood Coagulation Factors; Clinical Protocols; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hospitals; Humans; Piperazines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban	2016
Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures. The American journal of medicine, 2016, Volume: 129, Issue:11S Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antithrombins; Arginine; Dabigatran; Deprescriptions; Emergencies; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Piperazines; Prothrombin Time; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Surgical Procedures, Operative	2016
Preclinical and Clinical Data for Factor Xa and "Universal" Reversal Agents. The American journal of medicine, 2016, Volume: 129, Issue:11S Topics: Animals; Antidotes; Arginine; Atrial Fibrillation; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Piperazines; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thromboembolism	2016
Introduction to direct oral anticoagulants and rationale for specific reversal agents. The American journal of emergency medicine, 2016, Volume: 34, Issue:11S Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Arginine; Factor Xa; Humans; Piperazines; Recombinant Proteins	2016
Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols. The American journal of emergency medicine, 2016, Volume: 34, Issue:11S Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Clinical Protocols; Dabigatran; Emergency Treatment; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hospitals; Humans; Patient Selection; Piperazines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Surgical Procedures, Operative; Thiazoles	2016
Discontinuation and management of direct-acting anticoagulants for emergency procedures. The American journal of emergency medicine, 2016, Volume: 34, Issue:11S Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Blood Coagulation Tests; Emergency Treatment; Factor Xa; Hemorrhage; Humans; Perioperative Care; Piperazines; Recombinant Proteins; Withholding Treatment	2016
Preclinical and clinical data for factor Xa and "universal" reversal agents. The American journal of emergency medicine, 2016, Volume: 34, Issue:11S Topics: Animals; Anticoagulants; Arginine; Clinical Trials as Topic; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Piperazines; Recombinant Proteins	2016
Clinical implications of reversal agents for direct oral anticoagulants. Future cardiology, 2017, Volume: 13, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Arginine; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Piperazines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Venous Thromboembolism	2017
Reversal of direct oral anticoagulants. British journal of hospital medicine (London, England : 2005), 2017, Mar-02, Volume: 78, Issue:3 Topics: Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antithrombins; Arginine; Blood Coagulation Factors; Coagulants; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Intracranial Hemorrhages; Male; Partial Thromboplastin Time; Piperazines; Prothrombin Time; Recombinant Proteins; Thrombin Time	2017
The role of new oral anticoagulants in orthopaedics: an update of recent evidence. European journal of orthopaedic surgery & traumatology : orthopedie traumatologie, 2017, Volume: 27, Issue:5 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Blood Coagulation Tests; Dabigatran; Factor Xa; Hemorrhage; Humans; Orthopedic Procedures; Piperazines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Venous Thromboembolism	2017
[State of the art: Direct oral anticoagulants and transfusion]. Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2017, Volume: 24, Issue:3 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Arginine; Blood Coagulation Factors; Blood Transfusion; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Piperazines; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thrombophilia	2017
Reversal of direct oral anticoagulants. Vascular health and risk management, 2017, Volume: 13 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Blood Coagulation; Coagulants; Factor Xa; Hemorrhage; Humans; Piperazines; Recombinant Proteins; Risk Factors; Treatment Outcome	2017
Reversal agents for non-vitamin K antagonist oral anticoagulants. Nature reviews. Cardiology, 2018, Volume: 15, Issue:5 Topics: Administration, Oral; Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Arginine; Blood Coagulation; Blood Loss, Surgical; Coagulants; Factor Xa; Hemorrhage; Humans; Perioperative Care; Piperazines; Postoperative Hemorrhage; Recombinant Proteins; Risk Assessment; Risk Factors; Treatment Outcome	2018
Advances in Stroke 2017. Stroke, 2018, Volume: 49, Issue:5 Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antihypertensive Agents; Arginine; Delivery of Health Care; Factor Xa; Health Policy; Humans; Hypertension; Intracranial Hemorrhages; Outcome Assessment, Health Care; Piperazines; Recombinant Proteins; Stroke; Stroke Rehabilitation; Thrombectomy; Thrombolytic Therapy	2018
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. Thrombosis and haemostasis, 2019, Volume: 119, Issue:1 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Atrial Fibrillation; Benzamides; Biomarkers; Blood Coagulation; Clinical Trials as Topic; Dabigatran; Drug Administration Schedule; Factor Xa; Heart Diseases; Humans; Piperazines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Risk; Rivaroxaban; Stroke; Thiazoles; Thrombin; Venous Thromboembolism; Vitamin K; Warfarin	2019
Antidotes for reversal of direct oral anticoagulants. Pharmacology & therapeutics, 2019, Volume: 204 Topics: Animals; Antibodies, Monoclonal, Humanized; Arginine; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Piperazines; Recombinant Proteins	2019
Current Strategies for the Management of Bleeding Associated with Direct Oral Anticoagulants and a Review of Investigational Reversal Agents. The Journal of emergency medicine, 2020, Volume: 58, Issue:2 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Blood Coagulation Factors; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Piperazines; Practice Guidelines as Topic; Recombinant Proteins	2020
A short review of ciraparantag in perspective of the currently available anticoagulant reversal agents. Drug discovery today, 2022, Volume: 27, Issue:10 Topics: Administration, Oral; Anticoagulant Reversal Agents; Anticoagulants; Anticoagulation Reversal; Antidotes; Arginine; Hemorrhage; Heparin; Humans; Piperazines; Recombinant Proteins	2022

Trials

3 trial(s) available for arginine and per977

Article	Year
Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban. Thrombosis and haemostasis, 2017, 01-26, Volume: 117, Issue:2 Topics: Administration, Oral; Adult; Arginine; Blood Coagulation; Double-Blind Method; Drug Monitoring; Factor Xa Inhibitors; Humans; Injections, Intravenous; Male; North Carolina; Piperazines; Pyridines; Thiazoles; Whole Blood Coagulation Time	2017
Ciraparantag, an anticoagulant reversal drug: mechanism of action, pharmacokinetics, and reversal of anticoagulants. Blood, 2021, 01-07, Volume: 137, Issue:1 Topics: Animals; Anticoagulants; Arginine; Blood Coagulation; Female; Half-Life; Hemorrhage; Humans; Male; Piperazines; Rats; Rats, Sprague-Dawley	2021
Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects. European heart journal, 2022, Mar-07, Volume: 43, Issue:10 Topics: Administration, Oral; Adult; Aged; Anticoagulants; Arginine; Dabigatran; Healthy Volunteers; Humans; Middle Aged; Piperazines; Pyrazoles; Pyridones; Rivaroxaban	2022

Other Studies

10 other study(ies) available for arginine and per977

Article	Year
Use of PER977 to reverse the anticoagulant effect of edoxaban. The New England journal of medicine, 2014, Nov-27, Volume: 371, Issue:22 Topics: Arginine; Blood Coagulation; Factor Xa Inhibitors; Heparin Antagonists; Humans; Piperazines; Pyridines; Thiazoles	2014
Novel oral anticoagulants and reversal agents: Considerations for clinical development. American heart journal, 2015, Volume: 169, Issue:6 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Cardiovascular Diseases; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Piperazines; Recombinant Proteins; Stroke	2015
Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharm European heart journal, 2017, 06-07, Volume: 38, Issue:22 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Arginine; Consensus; Dabigatran; Evidence-Based Medicine; Factor Xa; Forecasting; Hemorrhage; Humans; Piperazines; Recombinant Proteins; Risk Factors; Thrombosis; Vitamin K	2017
[Antidotes for the new oral anticoagulants: Reality and expectations]. Medicina clinica, 2016, Jun-03, Volume: 146, Issue:11 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Coagulants; Factor Xa; Hemorrhage; Humans; Piperazines; Recombinant Proteins; Treatment Outcome	2016
Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin. Thrombosis research, 2016, Volume: 146 Topics: Adolescent; Adult; Aged; Anticoagulants; Arginine; Female; Healthy Volunteers; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Piperazines; Young Adult	2016
Ciraparantag for enoxaparin reversal: Adding to the evidence. Thrombosis research, 2016, Volume: 146 Topics: Arginine; Enoxaparin; Humans; Piperazines	2016
Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors. Blood advances, 2018, 08-28, Volume: 2, Issue:16 Topics: Administration, Oral; Arginine; Blood Coagulation; Dendrimers; Factor Xa; Factor Xa Inhibitors; Heparin; Humans; Piperazines; Recombinant Proteins	2018
Management of epistaxis in patients on novel oral anticoagulation therapy. The Journal of laryngology and otology, 2020, Volume: 134, Issue:4 Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antithrombins; Arginine; Awareness; Dabigatran; Epistaxis; Factor Xa; Factor Xa Inhibitors; First Aid; Humans; Male; Piperazines; Prevalence; Recombinant Proteins; Rivaroxaban; Severity of Illness Index	2020
Ciraparantag: the next anticoagulant airbag? Blood, 2021, 01-07, Volume: 137, Issue:1 Topics: Air Bags; Anticoagulants; Arginine; Pharmaceutical Preparations; Piperazines	2021
Ciraparantag as a potential universal anticoagulant reversal agent. European heart journal, 2022, 03-07, Volume: 43, Issue:10 Topics: Anticoagulants; Anticoagulation Reversal; Arginine; Humans; Piperazines	2022